Corvus Pharmaceuticals CRVS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Corvus Pharmaceuticals (CRVS) reported comprehensive income (loss), net of tax, attributable to parent of -$13.92M in Q1 2026.
- How has Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 191.4% year-over-year, from $15.23M to -$13.92M.
- What is the long-term trend for Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -22.5% compound annual growth rate (CAGR), from -$41.38M to -$14.89M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is a comprehensive measure of all changes in equity during a period, excluding transactions with owners, encompassing both net income and other comprehensive income items. It provides a holistic view of the company's total financial performance by including unrealized gains or losses that bypass the traditional income statement. Investors use this to evaluate the total economic impact of all financial activities on the company's net worth.